Concepts (170)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Appendiceal Neoplasms | 17 | 2026 | 55 | 5.210 |
Why?
|
| Peritoneal Neoplasms | 18 | 2026 | 196 | 3.240 |
Why?
|
| Circulating Tumor DNA | 6 | 2026 | 82 | 2.700 |
Why?
|
| Colorectal Neoplasms | 15 | 2026 | 1120 | 2.320 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 21 | 2026 | 2666 | 2.020 |
Why?
|
| Adenocarcinoma | 10 | 2026 | 1215 | 1.880 |
Why?
|
| Neoplasm Recurrence, Local | 7 | 2026 | 1538 | 1.800 |
Why?
|
| Hyperthermia, Induced | 9 | 2026 | 77 | 1.650 |
Why?
|
| Colonic Neoplasms | 8 | 2026 | 592 | 1.620 |
Why?
|
| Rectal Neoplasms | 7 | 2026 | 139 | 1.330 |
Why?
|
| Biomarkers, Tumor | 6 | 2026 | 1786 | 1.180 |
Why?
|
| Chromogranins | 1 | 2026 | 17 | 0.930 |
Why?
|
| GTP-Binding Protein alpha Subunits, Gs | 1 | 2026 | 24 | 0.930 |
Why?
|
| Fluorouracil | 9 | 2026 | 543 | 0.870 |
Why?
|
| Mutation | 8 | 2026 | 4443 | 0.760 |
Why?
|
| Cytoreduction Surgical Procedures | 16 | 2025 | 105 | 0.750 |
Why?
|
| Neoplasm Staging | 8 | 2026 | 2087 | 0.610 |
Why?
|
| Survival Rate | 9 | 2026 | 2057 | 0.580 |
Why?
|
| Precision Medicine | 1 | 2024 | 512 | 0.580 |
Why?
|
| Celecoxib | 3 | 2026 | 34 | 0.480 |
Why?
|
| Practice Guidelines as Topic | 5 | 2025 | 1116 | 0.470 |
Why?
|
| Neoadjuvant Therapy | 5 | 2026 | 477 | 0.460 |
Why?
|
| Humans | 51 | 2026 | 98799 | 0.450 |
Why?
|
| Retrospective Studies | 16 | 2026 | 11104 | 0.450 |
Why?
|
| Prognosis | 8 | 2026 | 4139 | 0.450 |
Why?
|
| Middle Aged | 22 | 2026 | 29642 | 0.440 |
Why?
|
| Class I Phosphatidylinositol 3-Kinases | 2 | 2026 | 84 | 0.430 |
Why?
|
| Male | 25 | 2026 | 47475 | 0.410 |
Why?
|
| Female | 26 | 2026 | 51997 | 0.390 |
Why?
|
| Aged | 17 | 2026 | 21986 | 0.380 |
Why?
|
| Follow-Up Studies | 5 | 2026 | 4049 | 0.380 |
Why?
|
| Leucovorin | 7 | 2026 | 205 | 0.380 |
Why?
|
| Pancreatic Neoplasms | 3 | 2024 | 782 | 0.370 |
Why?
|
| Adult | 17 | 2026 | 29698 | 0.370 |
Why?
|
| Delphi Technique | 6 | 2025 | 183 | 0.310 |
Why?
|
| Radiosurgery | 2 | 2024 | 352 | 0.310 |
Why?
|
| Consensus | 6 | 2025 | 308 | 0.300 |
Why?
|
| Liver Neoplasms | 3 | 2024 | 840 | 0.280 |
Why?
|
| DNA Mismatch Repair | 2 | 2026 | 60 | 0.280 |
Why?
|
| Antibodies, Monoclonal, Humanized | 2 | 2026 | 1105 | 0.280 |
Why?
|
| Aged, 80 and over | 6 | 2025 | 7461 | 0.280 |
Why?
|
| Capecitabine | 2 | 2026 | 103 | 0.270 |
Why?
|
| Microsatellite Instability | 3 | 2024 | 69 | 0.270 |
Why?
|
| Age of Onset | 2 | 2026 | 369 | 0.270 |
Why?
|
| Organoplatinum Compounds | 5 | 2026 | 95 | 0.270 |
Why?
|
| Disease-Free Survival | 6 | 2026 | 1196 | 0.260 |
Why?
|
| Combined Modality Therapy | 7 | 2024 | 1754 | 0.250 |
Why?
|
| Phenylurea Compounds | 2 | 2024 | 112 | 0.240 |
Why?
|
| Cholecalciferol | 1 | 2026 | 37 | 0.240 |
Why?
|
| Chemotherapy, Adjuvant | 5 | 2026 | 527 | 0.240 |
Why?
|
| Pelvis | 1 | 2026 | 106 | 0.230 |
Why?
|
| MutS Homolog 2 Protein | 1 | 2024 | 33 | 0.210 |
Why?
|
| Watchful Waiting | 1 | 2025 | 77 | 0.210 |
Why?
|
| Cyclooxygenase 2 Inhibitors | 1 | 2024 | 36 | 0.210 |
Why?
|
| Patient Preference | 1 | 2025 | 136 | 0.200 |
Why?
|
| Quinolines | 1 | 2024 | 97 | 0.200 |
Why?
|
| Peritoneum | 4 | 2024 | 52 | 0.200 |
Why?
|
| Surgical Oncology | 1 | 2023 | 34 | 0.190 |
Why?
|
| Patient Participation | 1 | 2025 | 251 | 0.190 |
Why?
|
| Mutation, Missense | 1 | 2024 | 312 | 0.190 |
Why?
|
| Appendix | 1 | 2023 | 33 | 0.190 |
Why?
|
| Vaccines | 1 | 2024 | 86 | 0.190 |
Why?
|
| Cancer Vaccines | 1 | 2024 | 168 | 0.180 |
Why?
|
| Quality Assurance, Health Care | 1 | 2024 | 229 | 0.180 |
Why?
|
| Neuroendocrine Tumors | 1 | 2024 | 158 | 0.180 |
Why?
|
| Antineoplastic Agents | 2 | 2024 | 2386 | 0.180 |
Why?
|
| C-Reactive Protein | 1 | 2023 | 219 | 0.170 |
Why?
|
| Molecular Targeted Therapy | 1 | 2024 | 331 | 0.170 |
Why?
|
| Ataxia Telangiectasia Mutated Proteins | 1 | 2021 | 65 | 0.170 |
Why?
|
| Research Design | 1 | 2025 | 652 | 0.170 |
Why?
|
| DNA Breaks, Double-Stranded | 1 | 2021 | 73 | 0.170 |
Why?
|
| Palliative Care | 1 | 2023 | 291 | 0.170 |
Why?
|
| Germ-Line Mutation | 1 | 2024 | 404 | 0.170 |
Why?
|
| Lung Neoplasms | 2 | 2023 | 2474 | 0.160 |
Why?
|
| Mitoxantrone | 1 | 2020 | 65 | 0.150 |
Why?
|
| Clinical Trials as Topic | 1 | 2025 | 1128 | 0.150 |
Why?
|
| Tumor Microenvironment | 1 | 2024 | 621 | 0.150 |
Why?
|
| Biomedical Research | 1 | 2025 | 477 | 0.150 |
Why?
|
| Etoposide | 1 | 2020 | 207 | 0.150 |
Why?
|
| Cytarabine | 1 | 2020 | 218 | 0.150 |
Why?
|
| Pyridines | 3 | 2024 | 317 | 0.130 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2021 | 642 | 0.130 |
Why?
|
| Neoplasms | 2 | 2024 | 3382 | 0.120 |
Why?
|
| Double-Blind Method | 3 | 2026 | 1793 | 0.120 |
Why?
|
| Kaplan-Meier Estimate | 3 | 2025 | 909 | 0.120 |
Why?
|
| Head and Neck Neoplasms | 1 | 2021 | 1091 | 0.100 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2023 | 1177 | 0.100 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2026 | 3622 | 0.100 |
Why?
|
| Leukemia, Myeloid, Acute | 1 | 2020 | 850 | 0.100 |
Why?
|
| Myeloproliferative Disorders | 1 | 2016 | 159 | 0.100 |
Why?
|
| Chemotherapy, Cancer, Regional Perfusion | 2 | 2023 | 18 | 0.100 |
Why?
|
| Neoplasm Grading | 2 | 2024 | 425 | 0.090 |
Why?
|
| Carcinoembryonic Antigen | 2 | 2023 | 40 | 0.090 |
Why?
|
| Treatment Outcome | 4 | 2026 | 9806 | 0.080 |
Why?
|
| Prospective Studies | 3 | 2024 | 4837 | 0.080 |
Why?
|
| Hypertension | 2 | 2026 | 791 | 0.070 |
Why?
|
| Recurrence | 2 | 2023 | 1274 | 0.070 |
Why?
|
| Immunotherapy | 2 | 2024 | 831 | 0.060 |
Why?
|
| Mitomycin | 1 | 2026 | 30 | 0.060 |
Why?
|
| Cohort Studies | 2 | 2023 | 3242 | 0.060 |
Why?
|
| Neutropenia | 1 | 2026 | 211 | 0.060 |
Why?
|
| Camptothecin | 1 | 2026 | 198 | 0.060 |
Why?
|
| Bevacizumab | 1 | 2026 | 255 | 0.060 |
Why?
|
| Quality of Life | 2 | 2024 | 1904 | 0.050 |
Why?
|
| Anilides | 1 | 2024 | 50 | 0.050 |
Why?
|
| Colectomy | 1 | 2026 | 211 | 0.050 |
Why?
|
| Tumor Cells, Cultured | 1 | 2026 | 1029 | 0.050 |
Why?
|
| Colorectal Neoplasms, Hereditary Nonpolyposis | 1 | 2024 | 54 | 0.050 |
Why?
|
| Cisplatin | 1 | 2026 | 578 | 0.050 |
Why?
|
| Thromboembolism | 1 | 2024 | 123 | 0.050 |
Why?
|
| Standard of Care | 1 | 2024 | 71 | 0.050 |
Why?
|
| B7-H1 Antigen | 1 | 2026 | 333 | 0.050 |
Why?
|
| Trifluridine | 1 | 2023 | 2 | 0.050 |
Why?
|
| Diarrhea | 1 | 2024 | 180 | 0.050 |
Why?
|
| Benzofurans | 1 | 2023 | 12 | 0.050 |
Why?
|
| Fatigue | 1 | 2024 | 187 | 0.050 |
Why?
|
| Advance Directives | 1 | 2023 | 64 | 0.050 |
Why?
|
| Preoperative Period | 1 | 2023 | 103 | 0.050 |
Why?
|
| Organ Sparing Treatments | 1 | 2023 | 54 | 0.050 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 1 | 2024 | 186 | 0.050 |
Why?
|
| HLA Antigens | 1 | 2024 | 239 | 0.050 |
Why?
|
| Anal Canal | 1 | 2023 | 94 | 0.050 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2026 | 1949 | 0.050 |
Why?
|
| Radiotherapy Planning, Computer-Assisted | 1 | 2024 | 215 | 0.040 |
Why?
|
| Sex Factors | 1 | 2025 | 1144 | 0.040 |
Why?
|
| Liquid Biopsy | 1 | 2022 | 51 | 0.040 |
Why?
|
| Monoterpenes | 1 | 2022 | 6 | 0.040 |
Why?
|
| Neoplasm Metastasis | 1 | 2026 | 1102 | 0.040 |
Why?
|
| Quinazolines | 1 | 2023 | 222 | 0.040 |
Why?
|
| Carcinoma, Pancreatic Ductal | 1 | 2024 | 158 | 0.040 |
Why?
|
| GPI-Linked Proteins | 1 | 2022 | 58 | 0.040 |
Why?
|
| Tumor Suppressor p53-Binding Protein 1 | 1 | 2021 | 13 | 0.040 |
Why?
|
| G2 Phase Cell Cycle Checkpoints | 1 | 2021 | 14 | 0.040 |
Why?
|
| Antigens, Neoplasm | 1 | 2024 | 366 | 0.040 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2023 | 286 | 0.040 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2026 | 671 | 0.040 |
Why?
|
| Incidence | 1 | 2026 | 1798 | 0.040 |
Why?
|
| Interleukin-6 | 1 | 2023 | 283 | 0.040 |
Why?
|
| Drug Combinations | 1 | 2022 | 202 | 0.040 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2023 | 402 | 0.040 |
Why?
|
| Immunologic Factors | 1 | 2022 | 180 | 0.040 |
Why?
|
| Preoperative Care | 1 | 2023 | 420 | 0.040 |
Why?
|
| Chemoradiotherapy | 1 | 2023 | 337 | 0.040 |
Why?
|
| Young Adult | 2 | 2026 | 7598 | 0.040 |
Why?
|
| Tumor Burden | 1 | 2021 | 330 | 0.040 |
Why?
|
| Postoperative Period | 1 | 2021 | 325 | 0.040 |
Why?
|
| Administration, Oral | 1 | 2022 | 677 | 0.040 |
Why?
|
| Mice, Nude | 1 | 2021 | 829 | 0.040 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2021 | 559 | 0.040 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2023 | 470 | 0.040 |
Why?
|
| Chronic Disease | 1 | 2023 | 991 | 0.040 |
Why?
|
| Prevalence | 1 | 2023 | 1396 | 0.040 |
Why?
|
| Biopsy | 1 | 2023 | 1226 | 0.040 |
Why?
|
| Cell Cycle Proteins | 1 | 2021 | 420 | 0.040 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2023 | 588 | 0.030 |
Why?
|
| Disease Progression | 1 | 2023 | 1621 | 0.030 |
Why?
|
| Length of Stay | 1 | 2021 | 889 | 0.030 |
Why?
|
| Surveys and Questionnaires | 1 | 2025 | 3058 | 0.030 |
Why?
|
| Inflammation | 1 | 2023 | 1134 | 0.030 |
Why?
|
| Biomarkers | 1 | 2023 | 2026 | 0.030 |
Why?
|
| Cell Proliferation | 1 | 2021 | 1801 | 0.030 |
Why?
|
| Apoptosis | 1 | 2021 | 1754 | 0.030 |
Why?
|
| Cell Line, Tumor | 1 | 2021 | 2913 | 0.030 |
Why?
|
| Illinois | 1 | 2016 | 531 | 0.030 |
Why?
|
| Adolescent | 1 | 2026 | 10168 | 0.020 |
Why?
|
| United States | 1 | 2025 | 8387 | 0.020 |
Why?
|
| Signal Transduction | 1 | 2021 | 3642 | 0.020 |
Why?
|
| Postoperative Complications | 1 | 2021 | 2719 | 0.020 |
Why?
|
| Mice | 1 | 2021 | 12762 | 0.020 |
Why?
|
| Animals | 1 | 2021 | 29045 | 0.010 |
Why?
|